中药抗肝纤维化作用的研究进展  

Research progress on anti-fibrotic effect of traditional Chinese medicine

作　　者：吕桂基 柏兆方 纪冬 LV Guiji;BAI Zhaofang;JI Dong(Senior Department of Hepatology,the Fifth Medical center of Chinese PLA General Hospital,Beijing 100039,China;Peking University 302 Clinical Medical School,100039,China)

机构地区：[1]解放军总医院第五医学中心肝病医学部,北京100039 [2]北京大学302临床医学院,100039

出　　处：《传染病信息》2023年第6期547-550,562,共5页Infectious Disease Information

基　　金：北京市自然科学基金(7222173);“十三五”国家科技重大专项(2018ZX10725506)。

摘　　要：肝纤维化是引起肝硬化和肝癌的重要过程。西药在这方面缺乏特效药物,而中药在肝纤维化和肝硬化的防治方面具有明显优势。本文对国内中药治疗肝纤维化临床研究存在的主要问题以及具有高级别循证医学证据的的临床研究进行综述,总结了中药发挥抗肝纤维化作用的主要机制,为进一步开展中药阻断、逆转肝纤维化的高质量研究提供参考。Liver fibrosis is an important step of cirrhosis and liver cancer.There is still no effective western medicine while traditional Chinese medicine(TCM)has significant superiority in the prevention and treatment of liver fibrosis and cirrhosis.This article focuses on the main problems on TCM treating liver fibrosis in clinical studies and clinical studies with high-level evidence-based medical evidence and summarizes the main mechanisms,providing references for further high-quality research on the blocking and reversing liver fibrosis with TCM.

关 键 词：中药 肝纤维化 肝硬化 

分 类 号：R575.2[医药卫生—消化系统] R97[医药卫生—内科学] R285[医药卫生—临床医学]